Axio BioPharma, an antibody manufacturing and process development company, announced recently that it is partnering with eMBR Genomics, a biotech company focused on early multi-cancer detection, to manufacture and distribute proprietary MKLP1 Pro Antibodies.

“Our partnership with eMBR Genomics is a testament to our shared mission of accelerating scientific discovery and improving patient outcomes,” Axio BioPharma Founder and CEO Justin Byers said in a statement. “The MKLP1 Pro antibody is not only a powerful research tool but also has the potential to be a game-changer in cancer and large extracellular vesicle diagnostics.”

According to a release, the partnership combines eMBR’s innovation in detecting Master Batch Records (MBRs) with Axio BioPharma’s manufacturing and global distribution network, making these proprietary antibodies accessible to scientists globally for the first time.

Both companies are located in Madison.